Barnes Dennig Private Wealth Management LLC Buys New Shares in Johnson & Johnson (NYSE:JNJ)

Barnes Dennig Private Wealth Management LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,410 shares of the company's stock, valued at approximately $400,000.

Several other large investors have also bought and sold shares of JNJ. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson during the fourth quarter worth $29,000. Conquis Financial LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson in the 4th quarter valued at $36,000. Finally, Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 5th. Barclays decreased their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Price Performance

NYSE JNJ traded up $0.34 during trading hours on Thursday, hitting $155.90. The company had a trading volume of 3,482,521 shares, compared to its average volume of 8,027,945. The firm has a 50 day simple moving average of $153.63 and a 200 day simple moving average of $153.88. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a market capitalization of $375.11 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 2.36 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.